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Abstract 
Over a period of five years, antemortem diagnosis of leptomeningeal spread was made in six of thirteen 
children with high grade astrocytomas. These included four of seven children with hemispheral tumors and 
two of six children with malignant brainstem gliomas. Leptomeningeal spread was diagnosed by the clinical 
picture and CSF profile. Meningeal spread occurred an average of 5 months (range 0-16) after initial 
diagnosis of tumor was made. Several patients responded well to local radiation and /or  chemotherapy. Mean 
survival after evidence of meningeal spread was 7 months (range 2 16) with one patient still alive. 
Meningeal spread of malignant childhood astrocytomas appears to be common and should be sought for in 
these patients as local radiation is beneficial. Serious consideration should be given to a controlled trial of 
prophylactic craniospinal radiation in thee tumors. The role of chemotherapy also requires further study. 
Introduction Materials and methods 
Glioblastoma multiforme is a malignant brain 
tumor  of glial origin with rapid growth and a fatal 
course. The tumor comprises approximately 
t5-20% of intracranial tumors in adults 3-11% in 
children (1). Its course is characterized by rapid 
local extension, sometimes with meningeal in- 
volvement, but it only occasionally metastasizes via 
cerebrospinal-fluid (CSF) pathways. This report 
describes our experience with six children with 
malignant astrocytomas (grades III  and IV) in 
whom spinal meningeal dissemination was diag- 
nosed. Our data suggest that CSF metastases may 
be a common complication of high grade astrocy- 
tomas, and that the use of spinal irradiation or 
chemotherapeutic agents is of short-term benefit. 
* Current Address: Pediatric Neurology, University of Michigan 
Medical Center, Ann Arbor, MI 48109 0010, USA. 
During the five year period, June 1977 to June 
1982, 90 new cases of primary brain or optic nerve 
tumors were diagnosed in children under the age of 
17 years at the Johns Hopkins Hospital pediatric 
neurology service. Of this group, 19 had supra- 
tentorial astrocytomas of which seven were grade 
III  or IV based on the pathologic criteria defined by 
Kernohan and Sayre (2). All 19 were biopsied. Ten 
had brainstem gliomas of which 4 had a clinical 
picture and course consistent with a low grade gli- 
oma (1 confirmed by biopsy) and 6 appeared to 
have a grade I I I - I V  glioma of which 3 were con- 
firmed by biopsy or CSF cytopathology (3). 
At many institutions, it is now common to res- 
trict the term glioblastoma multiforme to either 
grade IV astrocytomas or poorly differentiated 
anaplastic tumors of glial origin for which there is 
no definite evidence of a preexisting astrocytoma. 
Address for reprints: Bernard J D'Souza, MD, Duke University Medical Center, Box 3533, Durham, NC 27710, USA 
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Grade III astrocytomas are often referred to as 
malignant or anaplastic astrocytomas. Since it is 
difficult to clearly distinguish between grades three 
and four astrocytomas on the basis of a biopsy 
specimen (4), these cases have been combined and 
represent the study population. Autopsy permis- 
sion was denied. 
Results 
Among the thirteen children with high-grade 
tumors, six had clinical evidence of meningeal 
spread (Tables 1 and 2, Cases 1 6). There were no 
known instances of meningeal spread in the twelve 
children with grade I and II supratentorial astrocy- 
tomas or the four children with low-grade brain- 
stem gliomas. 
Of the six cases with evidence of meningeal 
spread, four had primary hemispheral tumors and 
two had pontine gliomas. The mean age of onset 
was 9. ! years for the hemispheral tumors (range: 5 
months-15 years) and 6.9 years for the brainstem 
gliomas (range: 4 9/12-9 years). Diagnoses were 
based on neuroradiographic studies in all cases and, 
in 5 of the cases, on tumor biopsy as well. Diagnosis 
in case 5 (not biopsied) was based on the clinical 
picture, CT scan and malignant tumor cells in CSF 
(Fig. 1A). Meningeal spread of the primary tumor 
in Cases 1-6 was diagnosed by clinical sympto- 
matology, neurological exam, CSF cytology (Fig. 
1B) and response to therapy. All but Case 5 had 
alterations in tone and most had diminution of 
reflexes. In the five cases (2-6) where a lunabar 
puncture or shunt tap was performed, all had ab- 
normal CSF findings (Table 3): cytopathology pos- 
itive in 3/5, increased protein 3/5, leukocytes 3/5. 
In patients 2 and 3, cranial computerized tomo- 
graphy showed abnormal tentorial or peri- 
ventricular enhancement, suggestive of CSF spread 
(Fig. 2). 
The mean interval between diagnosis of the 
primary tumor and evidence of meningeal involve- 
ment was five months (range 0-16 months). Follow- 
ing the diagnosis of spinal metastasis, all patients 
except Case 4 received either local cord irradiation, 
intrathecal methotrexate/thiotepa or systemic cis- 
platinum. Symptomatic response was noted in ev- 
ery case, ranging from diminution of pain to im- 
proved mobility. In the five deceased patients in 
whom antemortem diagnosis of meningeal spread 
was made, mean survival was 13 months from the 
diagnosis of the primary tumor (range: 3 22 
months) and 7 months from onset of myelopathy or 
radiculopathy (range: 2 16 months). One patient 
(Case 5) is still alive 14 months from the diagnosis 
of her tumor and of CSF spread. 
Table 1. Clinical summary  of patients. 
Case Age at time of Presenting symptoms Location of 
diagnosis tumors 
(years) 
Pathology Initial treatment Survival after 
diagnosis 
(months) 
1 10 Gait disorder R parietal 
2 15 Headache & seizure L temporo- 
parietal 
3 11 Seizures & lethargy L temporo- 
parietal 
4 5/12 Lethargy & decreased L temporo- 
feeding parietal 
5 9 Headaches & cranial Brainstem 
nerve palsies 












4500 rads whole brain 22 
together with metronidazole 
5400 rads to tumor  
3000 rads whole brain 3 
4500 rads whole brain 15 
5940 rads to tumor  
3960 rads to tumor 16 
4500 rads whole brain Alive at 
5400 rads posterior fossa 14 mo 
5040 rads posterior fossa 7 
Table 2. Clinical course of meningeal spread of patients with antemortem diagnosis. 
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Case Time from Clinical symptoms Status of primary Treatment  
diagnosis tumor at time of 













1 16 Radiating lumbosacral pain, Recurrence two 1200 rads to 
decreased sensation over months  prior to thoracolumbar spine 
TI0-TI2  distribution and meningeal spread 
diminished left knee jerk 
2 ! Nuchal rigidity, bilateral Enlarging, 2000 fads to 
arm weakness, back pain unresponsive to cervical spine 
and constipation therapy 
3 8 Low back pain Smaller by CT Cis-platinum 





4 0 Areflexia in lower Primary tumor  None 
extremities and meningeal 
spread diagnosed 
concurrently 
5 0 (Positive cytopathology Primary tumor  Received 3500 rads 
on shunt  tap) (swollen pons by spinal radiation 




6 5 Abrupt  onset of flaccid Progressively Steroids and 2100 
paraparesis, urinary enlarging rads to lumbosacral 
retention, and lax anal spine 








14 months  
Discussion 
Subarachnoid dissemination of malignant astro- 
cytoma/glioblastoma multiforme, outside the area 
of the primary tumor or operative site, was pre- 
viously considered quite rare (5, 6). Recently, how- 
ever, two large autopsy series of 77 patients with 
high grade astrocytomas, reported an approximate- 
ly 25% incidence of leptomeningeal metastases in 
patients ranging from 5 to 69 years, two of whom 
Table 3. CSF profile in patients with antemortem diagnosis of meningeal dissemination. 
Case Source Glucose Protein WBC RBC Cytopathology 
(mg/dl)  (mg/dl)  
1 
2 LP 8 234 102 7600 Positive 
3 LP 42 2610 88 2500 Necrotic 
debris 
4 LP 38 37 1 0 Positive 
5 Shunt  tap 72 5 0 0 Positive 
6 LP 92 77 26 628 Negative × 2 
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Fig. 1 CSF Cytopathology in malignant astrocytomas. (A) Tissue fragment of tumor  cells in the CSF in malignant brainstem glioma. 
Note the pleomorphism. Millipore filter X 787. (B) Group of tumor cells in CSF of patient with hemispheric malignant astrocytoma. 
Note the nuclear membrane thickness irregularity and prominent nucleoli. Millipore filter X 787. 
Fig. 2. CT evidence of CSF spread. Enhanced CT scan of the 
patient with left temporoparietal grade III glioma and clinical 
evidence of eerebrospinal dissemination. Note periventricular 
enhancement on left side suggesting CSF spread (arrow). 
were children (7, 8). In one of these series (8) eight of 
twelve cases were diagnosed antemortem. A small 
group of five patients with atypical juvenile astrocy- 
tomas and subarachnoid spread has also been re- 
ported (9). Spinal leptomeningeal metastases origi- 
nating f rom a pineal glioblastoma multiforme have 
also been reported (10). The frequency of sub- 
arachnoid spread of malignant brainstem gliomas 
remains controversial. One recent pediatric autop- 
sy series reported anatomical evidence of spread in 
seven of sixteen cases (11) while another  series with 
pediatric and adult cases found only one instance of 
subarachnoid spread in 25 cases (12). Finally, in a 
series with fifteen cases presenting as brainstem 
gliomas (13), five (33%) developed leptomeningeal 
metastases. 
This study differs f rom previous reports in that it 
is restricted to the pediatric population, specifically 
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children less than age 17. In our 5 year period of 
analysis none of the twelve patients with grade one 
or two supratentorial  astrocytomas nor the four 
patients with low-grade brainstam gliomas showed 
clinical evidence of subarachnoid spread. However, 
six out of thirteen cases of malignant astrocytomas 
(grades three or four) developed signs or symptoms 
of spinal meningeal seeding. 
For  the last three years of the study, evidence of 
meningeal spread was systematically looked for in 
all patients with high grade gliomas. In our pa- 
tients, there was no specific clinical pattern charac- 
teristic of leptomeningeal invasion. Findings in- 
cluded: stiff neck, back pain, sensory loss, 
hypotonia, weakness, depressed or absent reflexes 
and decreased anal tone or bowel and bladder in- 
continence. These are similar to those described in 
adults with meningeal spread and to adults with 
carcinomatous meningitis (8). Although it was 
sometimes difficult to determine whether these clin- 
ical findings represented meningeal spread or direct 
tumor extension, particularly in the case of brain 
stem gliomas, supportive evidence included the 
presence of nuchal rigidity, the CSF profile, or CT 
scans. As meningeal irritation may also be 
the result of cerebellar herniation, subarachnoid, 
hemorrhage, infectious meningitis or spillage of ne- 
crotic tumor  material producing a chemical menin- 
gitis (14), the analysis of CSF and cranial CT scans 
was helpful, especially when other findings consist- 
ent with a gliomatous meningitis .were present. 
Cranial CT scans demonstrated periventricular en- 
hancement in two patients, findings supportive of a 
disseminated meningeal tumor. The utility of cran- 
ial CT scans in providing reliable evidence for me- 
ningeal invasion has been described (15). Finally, 
the beneficial response of spinal cord signs and 
symptoms to local irradiation or chemotherapy has 
further supported the diagnosis of spinal subarach- 
noid spread. 
The current prognosis of patients with glioblas- 
toma multiforme is poor  (16). i t  has been suggested 
that the documentation of spinal spread is not 
worthwhile since the pr imary tumor  is fatal before 
symptoms of spinal seeding are present (17). In our 
cohort, spinal cord symptoms were the source of 
great discomfort and occurred months prior to 
death in all our cases. Significant, albeit temporary,  
improvements in the well-being of the patients were 
achieved with therapy. As newer primary che- 
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motherapeutic agents providing further increases in 
survival time are discovered, recognition of sub- 
arachnoid spread will become increasingly impor- 
tant. 
Some authorities now recommend prophylactic 
craniospinal irradiation for all childhood malig- 
nant cerebellar astrocytomas (18) or at least for 
selected infratentorial malignant astrocytomas 
(19). In one recent series of thirteen children with 
cerebellar malignant astrocytomas, five of six who 
received only cranial irradiation developed sub- 
arachnoid metastases while none of the seven who 
received craniospinal irradiation demonstrated 
subarachnoid spread (18). However, all of those 
who developed subarachnoid spread had received 
less than 5 000 fads to the primary tumor while 
those who did not had received 5 550-5 580 rads to 
the primary site raising the issue of whether the 
initial dose of radiation is the determining factor 
(20). Care must also be taken in differentiating 
subarachnoid spread defined by clinical symptoma- 
tology versus asymptomatic positive cytopathology 
(21). 
We report a 46% incidence of subarachnoid 
spread in malignant childhood astrocytomas with a 
.good temporary response to palliative therapy in 
the majority of patients. It is not clear when the 
spread occurs. If it occurs at the time of biopsy or 
initial tumor occurrence, as has been reported in 
germinomas, then prophylactic spinal irradiation is 
warranted. On the other hand, if subarachnoid 
spread occurs at the time of tumor recurrence or 
later, then prophylactic spinal radiation would be 
ineffective and contraindicated. A controlled trial 
of prophylactic spinal radiation versus radiation at 
the time of tumor spread merits consideration. 
Chemotherapy of brain tumors in general is still in 
its infancy. A continuous search for more effective 
chemotherapy is essential. 
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